These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 35001804

  • 1. Protein tyrosine phosphatase receptor type Z1 inhibits the cisplatin resistance of ovarian cancer by regulating PI3K/AKT/mTOR signal pathway.
    Wang P, Hu Y, Qu P, Zhao Y, Liu J, Zhao J, Kong B.
    Bioengineered; 2022 Jan; 13(1):1931-1941. PubMed ID: 35001804
    [Abstract] [Full Text] [Related]

  • 2. LDLR promotes autophagy-mediated cisplatin resistance in ovarian cancer associated with the PI3K/AKT/mTOR signaling pathway.
    Liu L, Sun YH, An R, Cheng RJ, Li N, Zheng JH.
    Kaohsiung J Med Sci; 2023 Aug; 39(8):779-788. PubMed ID: 37218642
    [Abstract] [Full Text] [Related]

  • 3. Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2.
    Xu L, Zhang B, Li W.
    Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576437
    [Abstract] [Full Text] [Related]

  • 4. Polypeptide LTX-315 reverses the cisplatin chemoresistance of ovarian cancer cells via regulating Beclin-1/PI3K/mTOR signaling pathway.
    Ma J, Liu L, Ling Y, Zheng J.
    J Biochem Mol Toxicol; 2021 Sep; 35(9):e22853. PubMed ID: 34309113
    [Abstract] [Full Text] [Related]

  • 5. REG3A promotes proliferation and DDP resistance of ovarian cancer cells by activating the PI3K/Akt signaling pathway.
    Jiang L, Liu Y, Liu M, Zheng Y, Chen L, Shan F, Ji J, Cao Y, Kai H, Kang X.
    Environ Toxicol; 2024 Jan; 39(1):85-96. PubMed ID: 37665173
    [Abstract] [Full Text] [Related]

  • 6. Silencing of miR-1246 Induces Cell Cycle Arrest and Apoptosis in Cisplatin-Resistant Ovarian Cancer Cells by Promoting ZNF23 Transcription.
    Cai L, Zhang Q, Du L, Zheng F.
    Cytogenet Genome Res; 2021 Jan; 161(10-11):488-500. PubMed ID: 34923485
    [Abstract] [Full Text] [Related]

  • 7. [Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer].
    Chen J, Wang Q, Zhang W, Li L.
    Zhonghua Fu Chan Ke Za Zhi; 2016 Apr 25; 51(4):285-92. PubMed ID: 27116987
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer.
    Zhang M, Wang J, Guo Y, Yue H, Zhang L.
    J Ovarian Res; 2023 Dec 19; 16(1):240. PubMed ID: 38115063
    [Abstract] [Full Text] [Related]

  • 10. Exosomal miR-21-5p derived from cisplatin-resistant SKOV3 ovarian cancer cells promotes glycolysis and inhibits chemosensitivity of its progenitor SKOV3 cells by targeting PDHA1.
    Zhuang L, Zhang B, Liu X, Lin L, Wang L, Hong Z, Chen J.
    Cell Biol Int; 2021 Oct 19; 45(10):2140-2149. PubMed ID: 34288231
    [Abstract] [Full Text] [Related]

  • 11. Propofol inhibits proliferation and cisplatin resistance in ovarian cancer cells through regulating the microRNA‑374a/forkhead box O1 signaling axis.
    Sun Y, Peng YB, Ye LL, Ma LX, Zou MY, Cheng ZG.
    Mol Med Rep; 2020 Mar 19; 21(3):1471-1480. PubMed ID: 32016462
    [Abstract] [Full Text] [Related]

  • 12. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
    Zhang Y, Huang S, Guo Y, Li L.
    Biomed Pharmacother; 2018 Oct 19; 106():1357-1363. PubMed ID: 30119207
    [Abstract] [Full Text] [Related]

  • 13. Chemotherapy-driven increases in the CDKN1A/PTN/PTPRZ1 axis promote chemoresistance by activating the NF-κB pathway in breast cancer cells.
    Huang P, Ouyang DJ, Chang S, Li MY, Li L, Li QY, Zeng R, Zou QY, Su J, Zhao P, Pei L, Yi WJ.
    Cell Commun Signal; 2018 Nov 29; 16(1):92. PubMed ID: 30497491
    [Abstract] [Full Text] [Related]

  • 14. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
    Wu D, Lu P, Mi X, Miao J.
    Arch Gynecol Obstet; 2018 Mar 29; 297(3):699-707. PubMed ID: 29327155
    [Abstract] [Full Text] [Related]

  • 15. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
    Zhang C, Wang M, Shi C, Shi F, Pei C.
    Biosci Trends; 2018 Jul 17; 12(3):309-316. PubMed ID: 29952351
    [Abstract] [Full Text] [Related]

  • 16. Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis.
    Long X, Song K, Hu H, Tian Q, Wang W, Dong Q, Yin X, Di W.
    J Exp Clin Cancer Res; 2019 Aug 07; 38(1):345. PubMed ID: 31391118
    [Abstract] [Full Text] [Related]

  • 17. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
    Gong T, Cui L, Wang H, Wang H, Han N.
    J Transl Med; 2018 Jun 14; 16(1):164. PubMed ID: 29898734
    [Abstract] [Full Text] [Related]

  • 18. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
    Kawaguchi H, Terai Y, Tanabe A, Sasaki H, Takai M, Fujiwara S, Ashihara K, Tanaka Y, Tanaka T, Tsunetoh S, Kanemura M, Ohmichi M.
    J Ovarian Res; 2014 Apr 09; 7():38. PubMed ID: 24713296
    [Abstract] [Full Text] [Related]

  • 19. TRIM47 inhibits cisplatin chemosensitivity and endoplasmic reticulum stress-induced apoptosis of ovarian cancer cells.
    Zhao J, Zhang J, Tong X, Zhao L, Cao R.
    Mol Cell Probes; 2024 Oct 09; 77():101978. PubMed ID: 39096978
    [Abstract] [Full Text] [Related]

  • 20. Label-free-based quantitative proteomic analysis of the inhibition of cisplatin-resistant ovarian cancer cell proliferation by cucurbitacin B.
    Yin S, Mai Z, Liu C, Xu L, Xia C.
    Phytomedicine; 2023 Mar 09; 111():154669. PubMed ID: 36681055
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.